Concepts (117)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Hodgkin Disease | 4 | 2026 | 306 | 1.490 |
Why?
|
| Burkitt Lymphoma | 3 | 2024 | 130 | 0.950 |
Why?
|
| Stem Cell Transplantation | 2 | 2017 | 224 | 0.920 |
Why?
|
| Malawi | 14 | 2026 | 349 | 0.910 |
Why?
|
| Methotrexate | 2 | 2025 | 348 | 0.910 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 5 | 2025 | 1325 | 0.900 |
Why?
|
| Capacity Building | 1 | 2025 | 26 | 0.880 |
Why?
|
| Sarcoma, Kaposi | 5 | 2025 | 128 | 0.850 |
Why?
|
| Hematologic Diseases | 1 | 2025 | 82 | 0.820 |
Why?
|
| Malnutrition | 2 | 2025 | 156 | 0.820 |
Why?
|
| Lymphoma, B-Cell | 1 | 2025 | 145 | 0.790 |
Why?
|
| Antimetabolites, Antineoplastic | 1 | 2025 | 194 | 0.780 |
Why?
|
| Mucositis | 1 | 2022 | 20 | 0.740 |
Why?
|
| Neoplasms | 7 | 2026 | 2974 | 0.680 |
Why?
|
| Lymphoma, Non-Hodgkin | 1 | 2022 | 163 | 0.660 |
Why?
|
| Positron-Emission Tomography | 2 | 2017 | 283 | 0.570 |
Why?
|
| Child | 26 | 2026 | 26171 | 0.520 |
Why?
|
| Transplantation, Autologous | 1 | 2017 | 253 | 0.500 |
Why?
|
| Radiopharmaceuticals | 1 | 2017 | 155 | 0.490 |
Why?
|
| Preoperative Care | 1 | 2017 | 357 | 0.440 |
Why?
|
| Africa South of the Sahara | 3 | 2025 | 120 | 0.420 |
Why?
|
| HIV Infections | 5 | 2026 | 2043 | 0.360 |
Why?
|
| Herpesvirus 8, Human | 2 | 2023 | 47 | 0.350 |
Why?
|
| Child, Preschool | 11 | 2026 | 15005 | 0.310 |
Why?
|
| Vincristine | 2 | 2020 | 188 | 0.280 |
Why?
|
| Retrospective Studies | 10 | 2026 | 17538 | 0.270 |
Why?
|
| Cyclophosphamide | 2 | 2020 | 425 | 0.260 |
Why?
|
| Adolescent | 12 | 2026 | 20797 | 0.260 |
Why?
|
| Humans | 27 | 2026 | 130055 | 0.250 |
Why?
|
| Follow-Up Studies | 6 | 2025 | 5164 | 0.250 |
Why?
|
| Reed-Sternberg Cells | 1 | 2026 | 18 | 0.240 |
Why?
|
| Laboratories, Hospital | 1 | 2025 | 24 | 0.220 |
Why?
|
| Legal Guardians | 1 | 2024 | 12 | 0.220 |
Why?
|
| Male | 16 | 2026 | 64375 | 0.220 |
Why?
|
| Anti-Retroviral Agents | 1 | 2026 | 154 | 0.210 |
Why?
|
| Cellular Senescence | 1 | 2026 | 216 | 0.210 |
Why?
|
| Female | 16 | 2026 | 70227 | 0.200 |
Why?
|
| Developing Countries | 1 | 2025 | 303 | 0.190 |
Why?
|
| Kasabach-Merritt Syndrome | 1 | 2023 | 15 | 0.190 |
Why?
|
| Drug Monitoring | 1 | 2025 | 289 | 0.180 |
Why?
|
| Malaria, Falciparum | 1 | 2022 | 58 | 0.180 |
Why?
|
| Quality of Life | 2 | 2022 | 2069 | 0.180 |
Why?
|
| Hospice and Palliative Care Nursing | 1 | 2022 | 17 | 0.180 |
Why?
|
| Malaria | 1 | 2022 | 93 | 0.170 |
Why?
|
| Wilms Tumor | 1 | 2023 | 117 | 0.170 |
Why?
|
| Hematology | 1 | 2022 | 42 | 0.170 |
Why?
|
| Infant | 7 | 2026 | 13266 | 0.160 |
Why?
|
| Creatinine | 1 | 2022 | 396 | 0.160 |
Why?
|
| Terminal Care | 1 | 2022 | 117 | 0.160 |
Why?
|
| Nutritional Status | 1 | 2022 | 297 | 0.160 |
Why?
|
| Lymphoproliferative Disorders | 1 | 2021 | 215 | 0.160 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2024 | 509 | 0.150 |
Why?
|
| Leukemia, Myeloid, Acute | 1 | 2025 | 607 | 0.150 |
Why?
|
| Anemia | 1 | 2023 | 352 | 0.140 |
Why?
|
| Kidney Neoplasms | 1 | 2023 | 420 | 0.140 |
Why?
|
| Practice Guidelines as Topic | 1 | 2025 | 1281 | 0.140 |
Why?
|
| Cell Differentiation | 1 | 2026 | 1906 | 0.140 |
Why?
|
| Vinblastine | 1 | 2018 | 54 | 0.140 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2025 | 1264 | 0.140 |
Why?
|
| Anemia, Sickle Cell | 1 | 2022 | 332 | 0.140 |
Why?
|
| Prednisolone | 1 | 2018 | 73 | 0.140 |
Why?
|
| Etoposide | 1 | 2018 | 111 | 0.140 |
Why?
|
| Lymphoma | 1 | 2021 | 326 | 0.140 |
Why?
|
| Bleomycin | 1 | 2018 | 116 | 0.140 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2024 | 907 | 0.140 |
Why?
|
| Dacarbazine | 1 | 2018 | 94 | 0.140 |
Why?
|
| Podophyllotoxin | 1 | 2017 | 6 | 0.130 |
Why?
|
| Carmustine | 1 | 2017 | 22 | 0.130 |
Why?
|
| Autografts | 1 | 2017 | 27 | 0.130 |
Why?
|
| Melphalan | 1 | 2017 | 45 | 0.130 |
Why?
|
| Survival Rate | 2 | 2025 | 2106 | 0.130 |
Why?
|
| Cytarabine | 1 | 2017 | 100 | 0.130 |
Why?
|
| Betacoronavirus | 1 | 2020 | 271 | 0.130 |
Why?
|
| Doxorubicin | 1 | 2018 | 289 | 0.130 |
Why?
|
| Prognosis | 3 | 2025 | 4845 | 0.120 |
Why?
|
| Prospective Studies | 2 | 2025 | 6401 | 0.120 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 337 | 0.110 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 348 | 0.110 |
Why?
|
| Pediatrics | 1 | 2025 | 1242 | 0.110 |
Why?
|
| Disease-Free Survival | 1 | 2017 | 902 | 0.110 |
Why?
|
| Cytokines | 1 | 2019 | 1332 | 0.100 |
Why?
|
| Pandemics | 1 | 2020 | 1112 | 0.100 |
Why?
|
| Adult | 4 | 2024 | 30999 | 0.090 |
Why?
|
| Risk Factors | 2 | 2026 | 10956 | 0.070 |
Why?
|
| Prevalence | 2 | 2025 | 2686 | 0.060 |
Why?
|
| Observational Studies as Topic | 1 | 2025 | 102 | 0.060 |
Why?
|
| Cross-Sectional Studies | 2 | 2023 | 3780 | 0.050 |
Why?
|
| Tanzania | 1 | 2023 | 68 | 0.050 |
Why?
|
| Nephrectomy | 1 | 2023 | 156 | 0.040 |
Why?
|
| Recurrence | 1 | 2025 | 1475 | 0.040 |
Why?
|
| Qualitative Research | 1 | 2024 | 709 | 0.040 |
Why?
|
| Virus Replication | 1 | 2023 | 607 | 0.040 |
Why?
|
| Immunity | 1 | 2021 | 178 | 0.040 |
Why?
|
| Autoimmunity | 1 | 2021 | 175 | 0.040 |
Why?
|
| Africa | 1 | 2020 | 135 | 0.040 |
Why?
|
| Medical Oncology | 1 | 2022 | 241 | 0.040 |
Why?
|
| Infant, Newborn | 2 | 2025 | 8547 | 0.040 |
Why?
|
| Lymphadenopathy | 1 | 2019 | 31 | 0.040 |
Why?
|
| Pain | 1 | 2022 | 431 | 0.040 |
Why?
|
| Apoptosis | 1 | 2026 | 1826 | 0.040 |
Why?
|
| Hospitals | 1 | 2022 | 430 | 0.040 |
Why?
|
| Combined Modality Therapy | 1 | 2023 | 1212 | 0.040 |
Why?
|
| Gene Expression Profiling | 1 | 2026 | 1800 | 0.040 |
Why?
|
| Patient Reported Outcome Measures | 1 | 2021 | 220 | 0.040 |
Why?
|
| Decision Making | 1 | 2024 | 711 | 0.040 |
Why?
|
| Neoplasm Staging | 1 | 2023 | 1277 | 0.040 |
Why?
|
| Health Services Accessibility | 1 | 2024 | 698 | 0.040 |
Why?
|
| Herpesvirus 4, Human | 1 | 2021 | 639 | 0.030 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2026 | 2008 | 0.030 |
Why?
|
| Incidence | 1 | 2026 | 3321 | 0.030 |
Why?
|
| Interleukin-6 | 1 | 2019 | 410 | 0.030 |
Why?
|
| Genetic Association Studies | 1 | 2021 | 819 | 0.030 |
Why?
|
| Palliative Care | 1 | 2022 | 445 | 0.030 |
Why?
|
| Genetic Testing | 1 | 2021 | 1094 | 0.030 |
Why?
|
| United States | 1 | 2023 | 11893 | 0.020 |
Why?
|
| Young Adult | 1 | 2021 | 9978 | 0.020 |
Why?
|
| Middle Aged | 1 | 2024 | 28303 | 0.010 |
Why?
|